OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, et al.
Annals of Oncology (2017) Vol. 28, Iss. 11, pp. 2754-2760
Open Access | Times Cited: 64
Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, et al.
Annals of Oncology (2017) Vol. 28, Iss. 11, pp. 2754-2760
Open Access | Times Cited: 64
Showing 26-50 of 64 citing articles:
Advanced nanomaterials targeting hypoxia to enhance radiotherapy
Jia Li, Wenting Shang, Yong Li, et al.
International Journal of Nanomedicine (2018) Vol. Volume 13, pp. 5925-5936
Open Access | Times Cited: 50
Jia Li, Wenting Shang, Yong Li, et al.
International Journal of Nanomedicine (2018) Vol. Volume 13, pp. 5925-5936
Open Access | Times Cited: 50
Targeted Nanomedicine to Treat Bone Metastasis
Isaac M. Adjei, Madison N. Temples, Shannon Brown, et al.
Pharmaceutics (2018) Vol. 10, Iss. 4, pp. 205-205
Open Access | Times Cited: 49
Isaac M. Adjei, Madison N. Temples, Shannon Brown, et al.
Pharmaceutics (2018) Vol. 10, Iss. 4, pp. 205-205
Open Access | Times Cited: 49
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer
Hanna K. Sanoff, Dominic H. Moon, Dominic T. Moore, et al.
Nanomedicine Nanotechnology Biology and Medicine (2019) Vol. 18, pp. 189-195
Open Access | Times Cited: 48
Hanna K. Sanoff, Dominic H. Moon, Dominic T. Moore, et al.
Nanomedicine Nanotechnology Biology and Medicine (2019) Vol. 18, pp. 189-195
Open Access | Times Cited: 48
Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy
Fei You, Changshou Gao
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 9, pp. 713-729
Closed Access | Times Cited: 47
Fei You, Changshou Gao
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 9, pp. 713-729
Closed Access | Times Cited: 47
Biochemical hallmarks-targeting antineoplastic nanotherapeutics
J. G. Han, He Dong, Tianyi Zhu, et al.
Bioactive Materials (2024) Vol. 36, pp. 427-454
Open Access | Times Cited: 6
J. G. Han, He Dong, Tianyi Zhu, et al.
Bioactive Materials (2024) Vol. 36, pp. 427-454
Open Access | Times Cited: 6
A Systematic Review of Clinical Trials on the Efficacy and Safety of CRLX101 Cyclodextrin-Based Nanomedicine for Cancer Treatment
Ana Serrano‐Martínez, Desirée Victoria-Montesinos, Ana María García-Muñoz, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1824-1824
Open Access | Times Cited: 13
Ana Serrano‐Martínez, Desirée Victoria-Montesinos, Ana María García-Muñoz, et al.
Pharmaceutics (2023) Vol. 15, Iss. 7, pp. 1824-1824
Open Access | Times Cited: 13
Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Maria Urbanova, Marina Cihova, Verona Buociková, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115179-115179
Open Access | Times Cited: 11
Maria Urbanova, Marina Cihova, Verona Buociková, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115179-115179
Open Access | Times Cited: 11
Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Wenjie Wang, Yuk‐Ching Tse‐Dinh
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 9, pp. 730-740
Closed Access | Times Cited: 32
Wenjie Wang, Yuk‐Ching Tse‐Dinh
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 9, pp. 730-740
Closed Access | Times Cited: 32
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
Carolyn Krasner, Susana M. Campos, Chantay L. Young, et al.
Gynecologic Oncology (2021) Vol. 162, Iss. 3, pp. 661-666
Closed Access | Times Cited: 24
Carolyn Krasner, Susana M. Campos, Chantay L. Young, et al.
Gynecologic Oncology (2021) Vol. 162, Iss. 3, pp. 661-666
Closed Access | Times Cited: 24
HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies
Xin Wang, Zhenwu Du, Tianmin Xu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
Xin Wang, Zhenwu Du, Tianmin Xu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review
Sajad Fakhri, Seyed Zachariah Moradi, Farahnaz Faraji, et al.
Cancer and Metastasis Reviews (2023) Vol. 43, Iss. 1, pp. 501-574
Closed Access | Times Cited: 10
Sajad Fakhri, Seyed Zachariah Moradi, Farahnaz Faraji, et al.
Cancer and Metastasis Reviews (2023) Vol. 43, Iss. 1, pp. 501-574
Closed Access | Times Cited: 10
Chemistry and Biology of Camptothecin and Their Derivatives
Karol Kacprzak, Arleta Sierakowska
Springer eBooks (2025), pp. 1-50
Closed Access
Karol Kacprzak, Arleta Sierakowska
Springer eBooks (2025), pp. 1-50
Closed Access
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index
Jian‐ping Gong, Wenqiu Zhang, Joseph P. Balthasar
Cancers (2025) Vol. 17, Iss. 6, pp. 1032-1032
Open Access
Jian‐ping Gong, Wenqiu Zhang, Joseph P. Balthasar
Cancers (2025) Vol. 17, Iss. 6, pp. 1032-1032
Open Access
Cancer chemoprevention: signaling pathways and strategic approaches
Junling Ren, Guangli Yan, Le Yang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Junling Ren, Guangli Yan, Le Yang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Cyclodextrins as non-viral vectors in cancer theranostics: A review
Ge Qu, Han Xu, Lianghua Ma, et al.
International Journal of Biological Macromolecules (2025), pp. 143697-143697
Closed Access
Ge Qu, Han Xu, Lianghua Ma, et al.
International Journal of Biological Macromolecules (2025), pp. 143697-143697
Closed Access
Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines
Geoffrey M. Lynn, Richard Laga, Christopher M. Jewell
Cancer Letters (2019) Vol. 459, pp. 192-203
Open Access | Times Cited: 26
Geoffrey M. Lynn, Richard Laga, Christopher M. Jewell
Cancer Letters (2019) Vol. 459, pp. 192-203
Open Access | Times Cited: 26
Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
Revati Sharma, George Kannourakis, Prashanth Prithviraj, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 16
Revati Sharma, George Kannourakis, Prashanth Prithviraj, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 16
Stimuli-responsive polyprodrug for cancer therapy
Chia‐Chin Lin, Yixia Liang, Mingyan Guo, et al.
Materials Today Advances (2022) Vol. 15, pp. 100266-100266
Open Access | Times Cited: 16
Chia‐Chin Lin, Yixia Liang, Mingyan Guo, et al.
Materials Today Advances (2022) Vol. 15, pp. 100266-100266
Open Access | Times Cited: 16
Oxygen Sensing and Viral Replication: Implications for Tropism and Pathogenesis
Peter Liu, Peter Balfe, Jane A. McKeating, et al.
Viruses (2020) Vol. 12, Iss. 11, pp. 1213-1213
Open Access | Times Cited: 21
Peter Liu, Peter Balfe, Jane A. McKeating, et al.
Viruses (2020) Vol. 12, Iss. 11, pp. 1213-1213
Open Access | Times Cited: 21
Silica‐Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment
Steffi Tiburcius, Kannan Krishnan, Jae‐Hun Yang, et al.
The Chemical Record (2020) Vol. 21, Iss. 6, pp. 1535-1568
Closed Access | Times Cited: 21
Steffi Tiburcius, Kannan Krishnan, Jae‐Hun Yang, et al.
The Chemical Record (2020) Vol. 21, Iss. 6, pp. 1535-1568
Closed Access | Times Cited: 21
Approaches to combat hypoxia in cancer therapy and the potential for in silico models in their evaluation
Jake C. Forster, Loredana G. Marcu, Eva Bezak
Physica Medica (2019) Vol. 64, pp. 145-156
Closed Access | Times Cited: 21
Jake C. Forster, Loredana G. Marcu, Eva Bezak
Physica Medica (2019) Vol. 64, pp. 145-156
Closed Access | Times Cited: 21
When Cyclodextrins Met Data Science: Unveiling Their Pharmaceutical Applications through Network Science and Text-Mining
Juliana Rincón‐López, Yara C. Almanza-Arjona, Alejandro P. Riascos, et al.
Pharmaceutics (2021) Vol. 13, Iss. 8, pp. 1297-1297
Open Access | Times Cited: 16
Juliana Rincón‐López, Yara C. Almanza-Arjona, Alejandro P. Riascos, et al.
Pharmaceutics (2021) Vol. 13, Iss. 8, pp. 1297-1297
Open Access | Times Cited: 16
Novel Anticancer Drug Discovery Strategies Targeting Hypoxia-Inducible factors
Muhamad Mustafa, Mahmoud Rashed, Jean‐Yves Winum
Expert Opinion on Drug Discovery (2024)
Closed Access | Times Cited: 2
Muhamad Mustafa, Mahmoud Rashed, Jean‐Yves Winum
Expert Opinion on Drug Discovery (2024)
Closed Access | Times Cited: 2
Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma
Keith T. Schmidt, Cody J. Peer, Alwin D. R. Huitema, et al.
Journal of Pharmaceutical and Biomedical Analysis (2019) Vol. 181, pp. 113073-113073
Open Access | Times Cited: 18
Keith T. Schmidt, Cody J. Peer, Alwin D. R. Huitema, et al.
Journal of Pharmaceutical and Biomedical Analysis (2019) Vol. 181, pp. 113073-113073
Open Access | Times Cited: 18
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide
Keith T. Schmidt, Fatima Karzai, Marijo Bilušić, et al.
The Oncologist (2022) Vol. 27, Iss. 9, pp. 718-e694
Open Access | Times Cited: 10
Keith T. Schmidt, Fatima Karzai, Marijo Bilušić, et al.
The Oncologist (2022) Vol. 27, Iss. 9, pp. 718-e694
Open Access | Times Cited: 10
